International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
CrossRef
Works that cite this article, indexed by Crossref.
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Diabetologia 66(10) (2023)
Matthew Anson; Sizheng S. Zhao; Philip Austin; Gema H. Ibarburu; Rayaz A. Malik; Uazman Alam
Analysis of Prescription Patterns of Antidiabetic Medication in a County From North-Western Romania
Internal Medicine 22(1) (2025)
Cosmin Mihai Vesa
Fournier’s Gangrene in an HIV-Positive Patient Using a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report
Journal of Wound Management and Research 21(1) (2025)
Woohyuk Yoon; Joon Ho Lee
Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
Frontiers in Medicine 13 (2026)
Minghui Yin; Hongyi Tan; Shan Xie; Yun Kuang; Qian Wu; Junlong Ma; Chengxian Guo
ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes
Advances in Therapy 42(12) (2025)
Rodrigo O. Moreira; Nemencio A. Nicodemus; Abdurrahman Comlekci; Miao Yu; Mussa H. Almalki
Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients
Scientific Reports 13(1) (2023)
Sanghwa Park; Jiseon Jeong; Yunna Woo; Yeo Jin Choi; Sooyoung Shin
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
touchREVIEWS in Endocrinology 17(1) (2021)
Johan H Jendle; Francisco J Ampudia-Blasco; Martin Füchtenbusch; Paolo Pozzilli
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Clinical and Molecular Hepatology 27(2) (2021)
Karn Wijarnpreecha; Elizabeth S. Aby; Aijaz Ahmed; Donghee Kim
Early Use of SGLT2 Inhibitors in Heart Failure With Preserved Ejection Fraction: Quantitative Analysis of Cardiac Biomarkers, Renal Function, and In-Hospital Mortality
Revista de Gestão Social e Ambiental 19(2) (2025)
Luiz Francisco de Souza Neto; Camila Maria Bertão Carvalho; Laura Emilly de Moura Bezerra; Luciano Victor Vasconcelos Saldanha; Artur Freire Brito; Kerolaine Silva Fonseca; Fernando Paniago Santini; Dionéa Ferreira Ayres Viana; Hildo Santiago Reis de Aguiar; Amanda Pinheiro Oliveira; Mariana Mota Benevides de Oliveira; Nelso Gabriel Lippo Turmina; Luis Guilherme Rodrigues de Almeida Moutinho; Rebeca Carvalho Wanderley de Lima Lôbo; Layanna Pessoa Marçal de Oliveira; Raíssa Maria Silvestre Santos; Aurélia Lorena Toscano de Medeiros Borges de Méllo; Levy Alves Pinto Loureiro; Dulce Cerqueira Ferreira Cavalcanti; Ana Clara Onofre Brito Chaves; José Mateus da Silva Bomfim; Ellen Pereira Areal; Maria Eduarda Morales Rodrigues; Rodrigo Porcionato; Joseane Oliveira Braga Nascimento; Harley Davidson Rocha de Lima; Giovana Mendelski Pereira
The Evaluation of Cardiovascular Risk in Diabetic Patients
European Pharmaceutical Journal 69(1) (2022)
S. Kosirova; D. Rubintova; J. Lacka; J. Klimas; T. Foltanova; I. Tumova
Metabolic effects of empagliflozine
Diabetes Obesity Metabolic Syndrome(5) (2022)
Antonina Kedyk; Oleksandr Kutsyn
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
European Endocrinology 1(1) (2021)
Johan H Jendle; Francisco J Ampudia-Blasco; Martin Füchtenbusch; Paolo Pozzilli
SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Scientific Reports 15(1) (2025)
Birdie Huang; Chieh-Li Yen; Chao-Yi Wu; Chung-Ying Tsai; Jia-Jin Chen; Ching-Chung Hsiao; Yung-Chang Chen; I-Chang Hsieh; Huang-Yu Yang
A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume 14 (2021)
Lianglan Shen; Hongli Yang; Xingxing Fang; Huaxing Huang; Wubin Yao; Dongmei Chen; Yan Shen
A practical review of diabetes mellitus type 2 treatment in primary care
Romanian Journal of Internal Medicine 60(1) (2022)
Justin T. Call; Pedro Cortés; Dana M. Harris
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy
World Journal of Cardiology 13(12) (2021)
Mouhamed Nashawi; Mahmoud S Ahmed; Toka Amin; Mujahed Abualfoul; Robert Chilton
Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus
Frontiers in Endocrinology 16 (2025)
Haoyi Yang; Yuwen Zhang; Yuxin Hong; Yuan Wei; Yuning Zhu; Lei Huang; Yuanxun Yang; Runbin Sun; Juan Li
Cardiac Remodeling Post-myocardial Infarction: Novel Therapies—Narrative Review
Journal of Clinical Cardiology 7(1) (2026)
Faizan Wadood Siddiqui; Abieyuwa Tari-Ere Oshodin; Manahil Ali; Sherien Metry; Sheima Gaffar; Sawera Gul; Muhammad Ali Muzammil
Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy
Acta Diabetologica 63(3) (2025)
Utku Soyaltin; Ilgin Y. Simsir; Baris Akinci